Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $475.49, marking a -1.41% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 3.46%.

Vertex Pharmaceuticals Inc. closed 8.54% short of its 52-week high of $519.88, which the company achieved on November 8th.

Experts say the layoffs are already causing issues in drug development — and things may get far worse without critical ...

Vertex Pharmaceuticals has been the apple of investors' search engines, but its recent stock dip of 3.3% might have folks ...

The stock's rise snapped a three-day losing streak.

Global pharma and MedTech stocks rebound as U.S. President Donald Trump issues a 90-day pause on reciprocal tariffs for all ...

Shares in many large drugmakers initially fell Wednesday on the president's threat, only to rebound later when he announced a ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

Morgan Stanley raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $462 from $459 and keeps an Equal Weight rating on the ...

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...